Metformin, Careprost, Sildenafil, Tadalafil

All product prices are in US dollars.
US Brand Name Arixtra PF Ingection
Generic Name Fondaparinux sodium
Other Brand Name Arixtra PF Ingection
Packing 0.5ml
Manufacturer GSK
Form Injection
Strength 2.5mg/0.5ml
Country India

  • 1 x Syringe 2.5 mg/0.5ml $28.18
Available online
More Views

Details

Introduction

Fondaparinux sodium is an antithrombotic drug which prevents coagulation. It acts by inhibiting certain clotting factors which interrupts the clotting cascade thereby preventing the formation of thrombus. Fondaparinux sodium is rapidly absorbed after injection and has a 3 hour peak. Primarily it is distributed in the blood but there are some in the extravascular area. Elimination of the drug is through urine, and majority of it is unchanged.


Use

Fondaparinux sodium is used to prevent venous thromboembolic events postoperatively, such as deep vein thrombosis and pulmonary embolism. It also decreases the risk of thromboembolic complications due to immobility during acute illness. In cardiovascular cases, Fondaparinux sodium is used to treat unstable angina, myocardial infarction with non-ST elevation and ST segment elevation, acute coronary syndrome and refractory ischemia. Instructions for Use & Handling: Solutions that are administered by physiological routes except the gastrointestinal route should be inspected for clarity and discoloration prior to administration. During administration it should be injected subcutaneously or intravenously. Always remember that never Fondaparinux sodium should be administered intramuscularly. When administering intravenously, it should be through an existing line or using a small volume saline minibag. The pre-filled syringe has an automatic needle protection system to prevent injury immediately after injection. Disposal of unused syringe or waste product should be in accordance with local requirements. Instructions for Self-Administration: Observe hand hygiene with soap and water and dry with towel. Check expiration date of the syringe and inspect the solution for clarity. The presence of a small air bubble in the syringe is normal. Assume a sitting or lying position. The site of injection is commonly the lower abdominal area, at least 5 cm below the umbilical level. To reduce discomfort at the injection site, alternate the left and right side of the lower abdominal area at each injection. Rub an alcohol swab on the injection site to prevent entrance of microorganisms upon injection. Remove and discard the needle guard. Make a skin fold by pinching the skin between the thumb and forefinger. This is held during the entire injection. Hold the syringe between the fingers and insert the full length of the needle at a 90 degree angle in the skin fold. Inject all the contents of the syringe by pressing down on the plunger as far as it goes. Upon release of the plunger and the needle will withdraw automatically from the skin and retract into the security sleeve where it will be locked permanently preventing needle-stick injuries.


Side effects

The common symptoms that are experienced with the use of this drug are anemia, bleeding and edema on injection site.


Contraindication

This drug is contraindicated in patients who have known hypersensitivity to fondaparinux sodium. Clients who are active clinically significant bleeding and acute bacterial endocarditis are contraindicated to it.


storage

Store Fondaparinux sodium at temperatures less than 25 degree C but should not be frozen. If incorporated to a small volume saline minibag, it should be administered immediately or at room temperature within 24 hours.


Composition

Each pre-filled syringe contains Fondaparinux sodium 2.5 mg in 0.5 mL solution for injection. Its pH is between 5 and 8.


Important Precautions

It is very important to report any form of bleeding to your physician while on this drug. Hemorrhage is a very common side effect of Fondaparinux sodium. Avoid getting open wound injuries and watch out for symptoms of bleeding such as bruising, confusion, clammy skin, dizziness, hypotension, pale skin, tachycardia or rapid pulse, shortness of breath, weakness, chest pain, black stools, red urine, and abdominal pain. Usage of this injection in pregnant and lactating women is not prescribed unless the benefit outweighs the risk.


Dosage and administration

In the treatment of venous thromboembolic events postoperatively, thromboembolic complications, unstable angina (non ST segment elevation myocardial infarction), and ST segment elevation myocardial infarction, Fondaparinux sodium is given at 2.5 mg once a day, injected subcutaneously. This is given 6 hours after surgical closure and usually until the client is ambulant. In thromboembolic complications it is given within 6-14 days to have a therapeutic effect. In unstable angina and ST segment elevation myocardial infarction it is given up to 8 days or until hospital discharge. Treatment of deep vein thrombosis and pulmonary embolism depends on the client's weight. In clients who weigh more than 100 kilograms, 10 mg of Fondaparinux sodium is given; if 50-100 kilograms, 7.5 mg is given; and if less than 50 kilograms only 5 mg of Fondaparinux sodium is given. This treatment is continued for at least 5 days and until it is safe to give oral anticoagulants to maximize therapeutic effect.